Botulinum toxin type A as an alternative way to treat trigeminal neuralgia: a systematic review

Ostrowski, Hubert; Roszak, Justyna; Komisarek, Oskar

doi:10.5603/pjnns.a2019.0030

Cited by 10 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is growing evidence that BoNT-A may represent a safe and effective alternative for TN management. 150,[169][170][171] However, based on the low quality of evidence, the recommendation given for BoNT-A is weak and restricted to an add-on therapy for mediumterm treatment of TN. 79 It is now widely accepted that BoNT-A may induced analgesia independently of muscle relaxation but still involves its interaction with the SNAP receptor complex and consequent blockade of synaptic vesicle fusion.…”

Section: Pharmacological Alternatives To Cbzmentioning

confidence: 99%

Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments

2020

View full text Add to dashboard Cite

The trigeminal nerve (V) is the fifth and largest of all cranial nerves, and it is responsible for detecting sensory stimuli that arise from the craniofacial area. The nerve is divided into three branches: ophthalmic (V1), maxillary (V2), and mandibular (V3); their cell bodies are located in the trigeminal ganglia and they make connections with second-order neurons in the trigeminal brainstem sensory nuclear complex. Ascending projections via the trigeminothalamic tract transmit information to the thalamus and other brain regions responsible for interpreting sensory information. One of the most common forms of craniofacial pain is trigeminal neuralgia. Trigeminal neuralgia is characterized by sudden, brief, and excruciating facial pain attacks in one or more of the V branches, leading to a severe reduction in the quality of life of affected patients. Trigeminal neuralgia etiology can be classified into idiopathic, classic, and secondary. Classic trigeminal neuralgia is associated with neurovascular compression in the trigeminal root entry zone, which can lead to demyelination and a dysregulation of voltage-gated sodium channel expression in the membrane. These alterations may be responsible for pain attacks in trigeminal neuralgia patients. The antiepileptic drugs carbamazepine and oxcarbazepine are the first-line pharmacological treatment for trigeminal neuralgia. Their mechanism of action is a modulation of voltage-gated sodium channels, leading to a decrease in neuronal activity. Although carbamazepine and oxcarbazepine are the first-line treatment, other drugs may be useful for pain control in trigeminal neuralgia. Among them, the anticonvulsants gabapentin, pregabalin, lamotrigine and phenytoin, baclofen, and botulinum toxin type A can be coadministered with carbamazepine or oxcarbazepine for a synergistic approach. New pharmacological alternatives are being explored such as the active metabolite of oxcarbazepine, eslicarbazepine, and the new Nav1.7 blocker vixotrigine. The pharmacological profiles of these drugs are addressed in this review.

show abstract

Section: Pharmacological Alternatives To Cbzmentioning

confidence: 99%

Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments

2020

View full text Add to dashboard Cite

show abstract

“…The cleft upper lip scar is at risk of hypertrophy due to repetitive movements of the muscles that transmit tension forces that distract and widen the wound edges during it is healing. A Botulinum toxin type A is a natural neurotoxin, which inhibits the release of acetylcholine at neuromuscular junctions and causing relaxation of the muscle 21 . As presented by Chang et al, 12,13 BoNT‐A effectively inhibits the action of the orbicularis oris muscle, causing the tension decreasing at the level of the surgical wound.…”

Section: Discussionmentioning

confidence: 99%

Scar management in patients after cleft lip repair–Systematic review Cleft lip scar management

Bartkowska

Komisarek²

2020

J of Cosmetic Dermatology

Self Cite

View full text Add to dashboard Cite

Background Cleft lip is a commonly occurring congenital development defect. Primary cleft lip repair leads to cleft scar formation. The resulting scar often undergoes hypertrophy, which negatively affects facial esthetics, function, and the patient's mental health. Aims The systematic review presented here was carried out to answer the following question: What cleft lip scar management options exist and how effective are they? Methods The systematic review of the articles on scar management methods in cleft lip patients was done in accordance with the PRISMA checklist. The literature search was conducted via the PubMed and Google Scholar databases. Results A total of 95 items were obtained. Finally, nine works have been included in the systematic review. Among the obtained works, there is a variety of cleft lip scar management methods. All the presented methods of cleft lip scar management proved to be effective in cleft scar therapy. Conclusions Cleft lip scar management should be considered as a constant and mandatory element of the treatment plan in cleft patients. It is also worth considering creating detailed protocols of conduct for cases of cleft lip scaring which pay attention to existing needs, prevention/correction and problems of superficiality and depth.

show abstract

“…Current studies have shown that BTX-A is an effective and safe treatment for trigeminal neuralgia (Ostrowski et al, 2009a;Rubis & Juodzbalys, 2020). A recent study examining factors influencing the efficacy on BTX-A found that a higher success rate of BTX-A treatment was observed in patients aged 50 years or older, but the age factor did not make a significant difference in the time to recurrence of pain, the onset of effect, or peaktime after BTX-A treatment (Wu et al, 2019).…”

Section: Trigeminal Neuralgiamentioning

confidence: 99%

“…In addition, some cases have reported that BTX-A is equally effective in trigeminal neuralgia caused by multiple sclerosis, suggesting that BTX-A can also treat atypical trigeminal neuralgia (Calejo et al, 2019). Cases of intraoral botulinum toxin injections for trigeminal neuralgia have also been reported, with relief and no facial asymmetry and no adverse effects with repeated intraoral botulinum toxin injections (Dinan et al, 2020;Ostrowski et al, 2009a). The list of the randomized clinical trials of BTX-A for neuropathic pain is detailed below (Table 3).…”

Section: Trigeminal Neuralgiamentioning

confidence: 99%

“…Botulinum toxin type A (BTX-A) is widely used for its high affinity and good tolerability in clinical practice (Satriyasa, 2019). Studies have shown that BTX-A is sustainable and non-addictive in analgesia (Ostrowski et al, 2009a) and has good efficacy in myofascial tension pain, neurogenic pain and inflammatory pain. Because of the discussion above, the current article was designed to review the latest research progress of BTX-A in pain treatment in the last two years.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Advances in botulinum toxin type A for the treatment of pain

Jiang¹,

Huang²,

Yang³

et al. 2021

NRFHH

View full text Add to dashboard Cite

<i>Clostridium botulinum</i> (CB) is a Gram-positive anaerobic bacterium and a significant cause of food spoilage. Foodborne botulism occurs worldwide every year and even lead to death from respiratory distress in severe cases after eating botulism-contaminated food. The pathogenicity of CB lies in its ability to produce a potent neurotoxin, “botulinum toxin (BTX)”, for which eight different subtypes have already been isolated so far. Botulinum toxin type A (BTX-A) is widely used to treat critical clinical issues due to its good affinity and tolerability. Studies have shown that BTX-A injections effectively treat myofascial pain, inflammatory pain, and neuropathic pain. The current article mainly reviews the latest research progress using BTX-A in pain treatment during two years.

show abstract

Botulinum toxin type A as an alternative way to treat trigeminal neuralgia: a systematic review

Cited by 10 publications

References 0 publications

Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments

Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments

Scar management in patients after cleft lip repair–Systematic review Cleft lip scar management

Advances in botulinum toxin type A for the treatment of pain

Contact Info

Product

Resources

About